Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders. This segment also provides devices for general ophthalmological examination and care, including slit lamps, refractometers, tonometers, optical coherence tomography devices, and fundus cameras; and devices for functional diagnostics, as well as digital products for storage, evaluation, and sharing of clinical data. In addition, this segment offers surgical ophthalmology products comprising surgical microscopes, biometers, phacoemulsification, and vitrectomy devices; intraocular lenses for cataract patients; and systems and consumables for laser eye surgery. The Microsurgery segment provides products and solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, neuro, dental, and spinal surgeries. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Over the last 7 days, the market has dropped 1.0%, driven by losses in the Consumer Discretionary and Industrials sectors of 4.0% and 1.8%, respectively. As for the longer term, the market has actually risen by 12% in the last year. As for the next few years, earnings are expected to grow by 17% per annum. Market details ›